Literature DB >> 20176900

Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.

Carmen Betriu1, Gracia Morales, Icíar Rodríguez-Avial, Esther Culebras, María Gómez, Fátima López-Fabal, Juan J Picazo.   

Abstract

The in vitro activity of TR-700 (torezolid) was evaluated against a collection of 660 staphylococcal blood isolates. TR-700 showed excellent activity against all the staphylococci tested. The MIC(50) and MIC(90) values of TR-700, linezolid, daptomycin, and vancomycin against methicillin-resistant Staphylococcus aureus (MRSA) isolates were 0.25 and 0.5, 2 and 4, 0.5 and 0.5, and 1 and 2 microg/ml, respectively. TR-700 demonstrated greater in vitro potency than linezolid against staphylococci, including linezolid-resistant and vancomycin-nonsusceptible strains, and was 32-fold more active than linezolid against the seven cfr-positive MRSA strains tested.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20176900      PMCID： PMC2863658          DOI： 10.1128/AAC.01653-09

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  15 in total

1.  Emergence of linezolid resistance in a methicillin resistant Staphylococcus aureus strain.

Authors:  M Hentschke; B Saager; M A Horstkotte; S Scherpe; M Wolters; H Kabisch; R Grosse; P Heisig; M Aepfelbacher; H Rohde
Journal:  Infection       Date:  2007-12-28       Impact factor: 3.553

2.  TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens.

Authors:  Ronald N Jones; Gary J Moet; Helio S Sader; Rodrigo E Mendes; Mariana Castanheira
Journal:  J Antimicrob Chemother       Date:  2009-02-13       Impact factor: 5.790

3.  Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.

Authors:  David M Livermore; Shazad Mushtaq; Marina Warner; Neil Woodford
Journal:  J Antimicrob Chemother       Date:  2009-01-22       Impact factor: 5.790

4.  Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus.

Authors:  Gracia Morales; Juan J Picazo; Elvira Baos; Francisco J Candel; Ana Arribi; Beatriz Peláez; Raquel Andrade; María-Angeles de la Torre; José Fereres; Miguel Sánchez-García
Journal:  Clin Infect Dis       Date:  2010-03-15       Impact factor: 9.079

5.  Reversion to susceptibility in a linezolid-resistant clinical isolate of Staphylococcus aureus.

Authors:  Venkata G Meka; Howard S Gold; Amy Cooke; Lata Venkataraman; George M Eliopoulos; Robert C Moellering; Stephen G Jenkins
Journal:  J Antimicrob Chemother       Date:  2004-09-03       Impact factor: 5.790

6.  Acquisition of a natural resistance gene renders a clinical strain of methicillin-resistant Staphylococcus aureus resistant to the synthetic antibiotic linezolid.

Authors:  Seok-Ming Toh; Liqun Xiong; Cesar A Arias; Maria V Villegas; Karen Lolans; John Quinn; Alexander S Mankin
Journal:  Mol Microbiol       Date:  2007-06       Impact factor: 3.501

7.  In vitro activity of TR-700, the antibacterial moiety of the prodrug TR-701, against linezolid-resistant strains.

Authors:  K J Shaw; S Poppe; R Schaadt; V Brown-Driver; J Finn; C M Pillar; D Shinabarger; G Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2008-10-06       Impact factor: 5.191

8.  ZAAPS International Surveillance Program (2007) for linezolid resistance: results from 5591 Gram-positive clinical isolates in 23 countries.

Authors:  Ronald N Jones; Shigeru Kohno; Yasuo Ono; James E Ross; Katsunori Yanagihara
Journal:  Diagn Microbiol Infect Dis       Date:  2009-06       Impact factor: 2.803

9.  Emergence of linezolid-resistant Staphylococcus aureus during treatment of pulmonary infection in a patient with cystic fibrosis.

Authors:  Ana C Gales; Hélio S Sader; Soraya S Andrade; Larissa Lutz; Adão Machado; Afonso L Barth
Journal:  Int J Antimicrob Agents       Date:  2006-03-09       Impact factor: 5.283

10.  First report of cfr-mediated resistance to linezolid in human staphylococcal clinical isolates recovered in the United States.

Authors:  Rodrigo E Mendes; Lalitagauri M Deshpande; Mariana Castanheira; Joseph DiPersio; Michael A Saubolle; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191
View more
  10 in total

1.  Tedizolid phosphate.

Authors:  Dennis J Cada; Kyle Ingram; Danial E Baker
Journal:  Hosp Pharm       Date:  2014-11

2.  In vitro activity and microbiological efficacy of tedizolid (TR-700) against Gram-positive clinical isolates from a phase 2 study of oral tedizolid phosphate (TR-701) in patients with complicated skin and skin structure infections.

Authors:  Philippe Prokocimer; Paul Bien; Carisa Deanda; Chris M Pillar; Ken Bartizal
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

3.  Comparative in vivo efficacies of epithelial lining fluid exposures of tedizolid, linezolid, and vancomycin for methicillin-resistant Staphylococcus aureus in a mouse pneumonia model.

Authors:  Pamela R Tessier; Rebecca A Keel; Mao Hagihara; Jared L Crandon; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2012-02-21       Impact factor: 5.191

Review 4.  Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.

Authors:  George G Zhanel; Riley Love; Heather Adam; Alyssa Golden; Sheryl Zelenitsky; Frank Schweizer; Bala Gorityala; Philippe R S Lagacé-Wiens; Ethan Rubinstein; Andrew Walkty; Alfred S Gin; Matthew Gilmour; Daryl J Hoban; Joseph P Lynch; James A Karlowsky
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

5.  Comparative pharmacodynamics of the new oxazolidinone tedizolid phosphate and linezolid in a neutropenic murine Staphylococcus aureus pneumonia model.

Authors:  Alexander J Lepak; Karen Marchillo; Solen Pichereau; William A Craig; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2012-09-10       Impact factor: 5.191

6.  In vitro activity of tedizolid and linezolid against Staphylococcus epidermidis isolated from prosthetic joint infections.

Authors:  C Littorin; B Hellmark; Å Nilsdotter-Augustinsson; B Söderquist
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-03-22       Impact factor: 3.267

Review 7.  Antibacterial activity of recently approved antibiotics against methicillin-resistant Staphylococcus aureus (MRSA) strains: A systematic review and meta-analysis.

Authors:  Fei Liu; Sajad Rajabi; Chunhua Shi; Ghazale Afifirad; Nazanin Omidi; Ebrahim Kouhsari; Saeed Khoshnood; Khalil Azizian
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-08-17       Impact factor: 6.781

Review 8.  Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.

Authors:  Darrell McBride; Tamara Krekel; Kevin Hsueh; Michael J Durkin
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-02-16       Impact factor: 4.481

9.  Newer antibacterials in therapy and clinical trials.

Authors:  Simi S Paknikar; Sarala Narayana
Journal:  N Am J Med Sci       Date:  2012-11

Review 10.  Potential role of tedizolid phosphate in the treatment of acute bacterial skin infections.

Authors:  Olatz Urbina; Olivia Ferrández; Mercè Espona; Esther Salas; Irene Ferrández; Santiago Grau
Journal:  Drug Des Devel Ther       Date:  2013-04-03       Impact factor: 4.162
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.